Wall Street brokerages expect that Nightstar Therapeutics PLC (NASDAQ:NITE) will post earnings of ($0.39) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Nightstar Therapeutics’ earnings. The highest EPS estimate is ($0.33) and the lowest is ($0.42). The company is expected to announce its next earnings results on Monday, November 12th.
On average, analysts expect that Nightstar Therapeutics will report full year earnings of ($1.62) per share for the current fiscal year, with EPS estimates ranging from ($1.77) to ($1.51). For the next year, analysts expect that the company will post earnings of ($1.52) per share, with EPS estimates ranging from ($1.75) to ($1.38). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that cover Nightstar Therapeutics.
Nightstar Therapeutics (NASDAQ:NITE) last posted its earnings results on Monday, August 13th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.12.
NITE has been the subject of a number of research analyst reports. Chardan Capital reiterated a “buy” rating and issued a $40.00 target price on shares of Nightstar Therapeutics in a research note on Wednesday, June 6th. Mizuho lifted their target price on shares of Nightstar Therapeutics to $24.00 and gave the company a “buy” rating in a research note on Tuesday. Janney Montgomery Scott initiated coverage on shares of Nightstar Therapeutics in a report on Wednesday, August 22nd. They issued a “buy” rating and a $34.00 price target for the company. Zacks Investment Research raised shares of Nightstar Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 9th. Finally, UBS Group lowered shares of Nightstar Therapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday, June 27th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $29.86.
Shares of NASDAQ:NITE traded up $2.20 during trading on Friday, reaching $24.80. The stock had a trading volume of 223,904 shares, compared to its average volume of 76,508. Nightstar Therapeutics has a 52 week low of $10.01 and a 52 week high of $24.93. The stock has a market capitalization of $631.69 million and a P/E ratio of -15.21.
Several institutional investors have recently modified their holdings of NITE. Millennium Management LLC acquired a new stake in shares of Nightstar Therapeutics in the first quarter valued at approximately $507,000. Stanley Laman Group Ltd. acquired a new stake in shares of Nightstar Therapeutics in the second quarter valued at approximately $195,000. Woodford Investment Management Ltd acquired a new stake in shares of Nightstar Therapeutics in the second quarter valued at approximately $5,024,000. Bank of America Corp DE acquired a new stake in shares of Nightstar Therapeutics in the second quarter valued at approximately $132,000. Finally, Redmile Group LLC increased its holdings in shares of Nightstar Therapeutics by 0.9% in the second quarter. Redmile Group LLC now owns 1,785,446 shares of the company’s stock valued at $28,567,000 after purchasing an additional 16,500 shares in the last quarter. 28.62% of the stock is owned by institutional investors and hedge funds.
About Nightstar Therapeutics
Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia.
Featured Story: Average Daily Trade Volume – What You Need to Know
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.